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Abstract
Lung cancer treatment remains difficult because of multidrug resistance and adverse 
effects, and natural product molecules show powerful activity in lung cancer with few 
side effects. The molecular targets and efficacy of natural product molecules remain 
unclear. We described the molecular regulation of natural product molecules with 
antitumor activities, the antilung cancer activities and the clinical trials for lung cancer 
treatment of natural product molecules. The results support the updated systemic infor-
mation on the use of natural product molecules to prevent cancer progression and their 
constituents for lung cancer treatment.
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1. Introduction
Lung cancer treatment remains difficult because of multidrug resistance and adverse effects. 
Natural product molecules represent an attractive approach for lung cancer therapy with few 
side effects but high treatment outcome. Various natural product molecules have proven to be 
useful and effective in sensitizing conventional agents. Several natural product molecules can 
prevent the side effects of chemotherapy. Moreover, natural product molecules can improve 
the quality of life (QoL) and prolong the survival time of lung cancer patients. In this chapter, 
we summarize the molecular regulation mechanisms of natural product molecules and their 
antitumor effects on lung cancer in vitro and in vivo.
In lung cancer treatment, the molecular targets and efficacy of natural product molecules remain 
unclear. Thus, we reviewed the antitumor activities of natural product molecules in lung cancer 
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therapy. This chapter is mainly divided into three parts: the molecular regulation of natural 
product molecules with antitumor activities, the antilung cancer activities of natural product 
molecules in vivo, and the clinical trials on natural product molecules for lung cancer treatment.
On the basis of our critical analyses, we suggest the potential of natural product molecules 
that have been traditionally used for lung diseases, including cancer, and the discussion of 
data from in vitro or in vivo laboratory experimental models and clinical trials. We suggest 
that natural product molecules can be potent anticancer agents for lung cancer treatment and 
prevention by regulating multimolecular targets. The effects of natural product molecules are 
involved in angiogenesis, metastasis, and severe side effects.
Lung cancer is the leading cause of cancer death worldwide. Small-cell lung cancer (SCLC) 
and non–small-cell lung cancer (NSCLC) are the two main types of lung cancer. Smoking can 
induce most kinds of lung cancer. In addition, vinyl chloride, arsenic, cadmium, beryllium, 
chloride, and nickel chromates contribute to the occurrence of lung cancer. For lung cancer 
patients who are nonsmokers, their cancer is usually caused by a combination of genetic fac-
tors, as well as exposure to radon gas and air pollution [1, 2]. For lung cancer, early diagnosis 
is very important for patients to improve their survival rate. The cause of lung cancer did not 
show any obvious symptoms until the cancer began to metastasize to other organs.
Chemotherapy, radiotherapy, and surgery are the most widely used strategies in lung cancer 
treatment. However, standard chemotherapies present severe toxicity for patients and may 
result in limited survival benefit. Given that phytochemicals and antitumor herbs are less 
toxic, these agents are used to treat lung cancer, and the outcome has attracted recent reports 
and investigations [3]. To date, antilung cancer herbs have included 130 Chinese herbal medi-
cines with effective treatment effects. These herbs are classified on the basis of their actions: (1) 
clearing heat and toxin, (2) resolving dampness and phlegm, (3) regulating blood and Qi, (4) 
reinforcing Qi, and (5) nourishing Yin through their ethnopharmacological efficacies.
In this chapter, we discuss the ethnopharmacological effects of natural product molecules 
focusing on metastasis, angiogenesis, apoptosis, and clinical trial efficacy. In these reviews, 
the results support the updated systemic information on the use of natural product molecules 
to prevent cancer progression and their constituents for lung cancer treatment.
2. Molecular regulation of natural product molecules with 
antitumor activities
To develop useful agents for cancer therapy, the unique activity mechanisms of natural prod-
uct molecules should be studied. The molecular mechanisms of natural product molecules 
with anticancer activities are important for the development of many drug-targeted therapies 
for cancer treatment [4]. Molecular biology methods for high-risk individuals during early 
diagnosis, screening, and identification can help determine the prognosis of innovative treat-
ment and provide a novel point of view [5]. Significantly, target molecules should be consid-
ered for lung cancer treatment.
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2.1. Apoptosis and natural product molecules
Apoptosis involves a series of morphological alterations, such as plasma and nuclear mem-
brane blebbing, cell shrinkage, dissolution of nuclear lamina, and biochemical processes, 
which are responsible for the activation of apoptosis [6]. In Chinese medicine, the fruit and 
roots of Toona sinensis (Meliaceae) have been used for cancer therapy. Toona displayed glu-
cose uptake in 3T3-L1 adipocyte differentiation of fat and enhanced the antidiabetic activity 
[7]. T. sinensis leaf extract (TSL-1) inhibition of lung adenocarcinoma cell proliferation after 
24 hours can mediate apoptosis at 0.5 or 1 mg/mL. Ocimum gratissimum (OG) (Lamiaceae) is 
a perennial aromatic herb with antibacterial and antidiabetic activity in Taiwan and is tra-
ditionally used to treat gastrointestinal diseases. OG can activate apoptotic signaling mol-
ecules, such as caspase-3 and caspase-9, in A549 cells at a concentration of 0.5 or 0.8 mg/mL; 
thus, OG is a potentially useful candidate [8]. In lung cancer cell apoptosis, medicinal plants 
from many biologically active compounds are also known as potent inducers. Acacetin flavo-
noid polyphenol compound (5,7-dihydroxy-4′-methoxy-flavonoids) from Robinia pseudoacacia 
(legumes) can inhibit A549 cell proliferation (IC50 = 9.46 μm). By upregulating p53 and p21/
WAF1 proteins, acacia-induced apoptosis and cell cycle at the concentrations of 5 or 10 μM in 
A549 cells [9]. Dihydroartemisinin (DHA) is a derivative of artemisinin from Artemisia annua 
Altai Michael (Asteraceae) and is used to treat malaria; DHA can also induce apoptosis in 
human lung cancer cells. PG490 (triptolide), a diterpene triepoxide from Tripterygium wilfordii 
(Celastraceae), was significantly sensitized to Apo2L/TRAIL-induced apoptosis, but it did not 
significantly induce cell death in A549 cells. Acutiaporberine is a bisalkaloid from the pointed 
leaves of Thalictrum (Ranunculaceae); ritterazine B is one of the ritterazine analogues from 
Ritterella tokioka (Polyclinidae), and ursolic acid is a pentacyclic triterpene from Hedyotis diffusa 
(Rubiaceae); these agents were all reported to induce apoptosis in vitro. Ginseng extract (EAG) 
(Panax ginseng C.A. Meyer) exerts anticancer effects on Lewis lung carcinoma cells (LLC) 
and demonstrates weak activity in breast cancer and liver cancer cells; the results showed that 
lung cancer cells may be more likely to prompt treatment by EAG.
By modulation of ERK-p53 and NF-κB signaling, EAG revealed inhibition in vitro and in vivo 
of mouse LLC. Traditional Chinese herbal medicine significantly inhibited the proliferation 
of A549 cells, partly because of the inhibition of NF-κB activation induced by tumor necro-
sis factor alpha (TNF-α) [10]. H460 cell viability was reduced by plumbagin from Plumbago 
indica, and the A549 cell survival rate decreased to 17.6% at 15 μM [11]. By inhibiting the sur-
vival proteins Akt, NF-κB, Bcl-2, and survivin in H460 cells, plumbagin can induce apoptosis. 
In addition, many traditional herbs have induced apoptosis in lung cancer cells; other bio-
logically active substances have also induced apoptosis: glossogin from Glossogyne tenuifolia 
(Asteraceae), a novel ginsenoside 25-OCH(3)-PPD from Panax notoginseng (Araliaceae), deg-
uelin from Lonchocarpus utilis or Lonchocarpus urucu (Fabaceae), and elemene from Curcuma 
kwangsiensis (Zingiberaceae) [12].
2.2. Inhibitory effects of natural product molecules on angiogenesis and metastasis
Among the contributing factors to the spread and growth of lung cancer, angiogenesis is the 
most important process because it involves the growth of new blood vessels from preexisting 
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vessels. Angiogenesis is associated with the development and spread of lung cancer because 
it influences the growth of novel blood vessels [13]. Thus, blockage of angiogenesis is consid-
ered an important therapeutic target for lung cancer. In the past decade, clinical trials have 
been conducted on angiostatin, endostatin, solimastat, bevacizumab, and angiozyme-target-
ing vascular endothelial growth factor (VEGF) as a key factor of angiogenesis. Selected VEGF 
targets have shown survival benefits in patient therapy [14]. VEGF is also related to other 
indirect angiogenic factors, such as basic fibroblast growth factor (bFGF), platelet-derived 
growth factor (PDGF), and tumor growth factor alpha (TGF-α) [15].
As a medicinal herb, Ganoderma lucidum (Ganodermataceae) is a basidiomycete white rot fun-
gus, which is helpful to the treatment of various diseases such as cancer, HIV infection, diabe-
tes, asthma, and ulcers, as demonstrated in Korea, China, and Japan [16]. Thus, many experts 
suggest the use of G. lucidum for prostate, skin, ovarian, and colon cancer therapy [17–19].
The growth of PG cells in Balb/c nude mice significantly inhibited G. lucidum polysaccha-
rides. For human umbilical vein endothelial cells (HUVECs), G. lucidum polysaccharides also 
inhibited cell proliferation. Under hypoxic condition, G. lucidum polysaccharides inhibited 
the secretion of VEGF in lung cancer cells. By using chick chorioallantoic membrane (CAM) 
assay, G. lucidum polysaccharides were proven to exert an antiangiogenic effect on Balb/c 
mice. Overall, these results suggest that G. lucidum polysaccharides inhibited vascular cell 
proliferation in HUVECs. In human lung carcinoma PG cells, G. lucidum polysaccharides 
also reduced the secretion of VEGF. Generally, clinical researchers unexpectedly found that 
G. lucidum polysaccharides might positively influence chemo/radiotherapy by combining 
these compounds with the subgroups of advanced lung cancer patients, resulting in reversed 
immunosuppressive effects on traditional cancer therapy [20]. Although the antitumor activ-
ity against lung cancer has been recognized, we need to study its efficacy, safety, optimal 
concentration, and molecular targets for further research. The effect of VEGF alone or in 
combination with current therapies for lung cancer is also very important to be investigated 
through future pharmacokinetic research on animals and humans.
The most characteristic aspect of malignant neoplasm is metastasis, which is the leading cause 
of death in cancer patients [21]. Tumor cell dissociation, intravasation, invasion, and distribu-
tion to distant organs arrest cells in small vessels, resulting in adhesion to endothelial cells, 
extravasation, invasion of the target organ, and proliferation, which are all related to tumor 
metastasis. matrix metalloproteinases (MMPs) are related to metastasis and cancer invasion 
and are proteolytic enzymes in the extracellular matrix (ECM). MMP-2 and MMP-9 signifi-
cantly influence the metastatic processes among the MMP family [22, 23].
2.3. Reversion of multidrug resistance
The largest difficulty of chemotherapy against cancers is multidrug resistance (MDR) [24]. 
Cellular overproduction of p-glycoprotein (p-gp) is one of the influencing factors leading to 
MDR because it can transport various anticancer drugs outward the cell. To date, a series 
of compounds to reverse MDR by interfering with the p-gp function have been determined 
[25–27]. However, some MDR reversal agents may lead to the change of pharmacokinetics 
and even cause serious side effects. Many anticancer drugs such as docetaxel, gemcitabine, 
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and vinorelbine can overexpress MDR-associated proteins (MRPs), including pgp. Although 
this effect is helpful for inducing MDR in the treatment of NSCLC, new MDR reversal agents 
should be developed to avoid MDR and improve the effects of lung cancer therapy.
Stephania tetrandra (Menispermaceae) comprises a herbal formula, which is also called 
“Supplement energy and nourish lung” (SENL) in herbal medicines. Both S. tetrandra and G. 
lucidum (Ganodermataceae) demonstrate a MDR-reversal potential in SW1573/2R 120, adria-
mycin (ADM)-resistant lung cancer cells, and valproic acid (VPA) MDR SCLC. Solamargine 
(SM) suppressed MRPs in lung cancer cells, although SM is traditionally used to treat chest 
pains, pleurisy, pneumonia, toothache, and sore throat in India because of the major steroidal 
glycoalkaloid from Solanum incanum (Solanaceae). SM enhanced the sensitivity of apopto-
sis induction in tumor necrosis factor (TNF) and cisplatin-resistant lung cancer cells. After 
combining the treatment of SM and epirubicin, we observed that the apoptosis effect of che-
motherapy was improved in A549 cells [28, 29]. Hence, we believe that SM is a potential 
MDR-reversal agent [30]. A test also showed that additional bioactive phytochemicals might 
be potential MDR-reversal agents, which include a novel monoketone curcumin analog, EF24 
from Curcuma longa (Zingiberaceae), emodin (1,3,8-trihydroxy-6-methyl-anthraquinone) 
from Rheum palmatum (Polygonaceae), and elemene from C. kwangsiensis (Zingiberaceae) [31].
2.4. Reactive oxygen species (ROS) and lung cancer therapy
Recently, ROS signaling became the focus of research on lung cancer as well as other cancer 
therapies [32]. In recent lung cancer therapies, targeting ROS signaling was thought to be a 
striking method [33]. Notably, smoke-oxidative stress results in DNA damage and restrains 
survival signaling, which make proliferation out of control during the transfer of lung epithe-
lial cells [34–36]. Few studies have shown that some herbal extracts and their components can 
eliminate active oxygen in lung cancer cells.
In Korea, people maintain oral health by using Polygonum cuspidatum (Polygonaceae) because 
of its effect in reducing oral microorganisms; Koreans also use P. cuspidatum in the treatment 
of arthritis and urinary diseases [37]. P. cuspidatum extract contains alkaloids, phenolics, and 
sterol/terpenes and induces biological activities such as anti-inflammation, antioxidation, and 
anticancer effects [38]. In A549 and H1650 cells, the ethanol and ethyl acetate extracts of P. 
cuspidatum can eliminate 1,1-diphenyl-2-hydrazyl (DPPH) and hydroxyl radicals. The ethyl 
acetate fraction (EAF) of wampee peel [Clausena lansium Skeels (Rutaceae)] is obtained from 
a species of strongly scented evergreen trees in Southeast Asia. Similarly, in comparison with 
cisplatin, the EAF of wampee peel exerted increased antioxidant and anticancer effects on 
A549 lung cancer cells, SGC-7901 gastric cancer cells, and HepG2 liver cancer cells. Thus, 
wampee peel should be studied to develop a natural antioxidant and pharmaceutical supple-
ment because of the DPPH radical scavenging activity, reducing power, and superoxide scav-
enging activity.
Recently, Lawless et al. advised in their review paper that histone deacetylase (HDAC) can 
significantly regulate the oxidative stress pathways in the development of cancer in NSCLC 
[39–41]. The authors advised that HDAC can be consumed in several common foods such as 
sulforaphane from Brassica oleracea (Brassicaceae), curcumin from C. longa L. (Zingiberaceae), 
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and epigallocatechin 3-gallate (EGCG) from Camellia sinensis (Theaceae) to combat NSCLC 
and chronic obstructive pulmonary disease (COPD). Nevertheless, further research on HDAC 
inhibition is necessary to develop more efficient antitumor drugs from herbal medicine. The 
mechanism and molecular targets of natural product molecules against lung cancer were 
shown in Figures 1 and 2.
 Figure 1. Mechanism of natural product molecules against lung cancer.
 Figure 2. Targets and/or pathways effected by natural product molecules against lung cancer.
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3. Antilung cancer natural product molecules in the body
The allogeneic graft model or mice xenograft is a valuable tool in cancer biology evaluation of 
novel anticancer activity of drug(s). Antitumor activity test is employed to measure the inhibi-
tion of the tumor growth and survival time. In vivo mouse models and some active natural 
product molecules also showed influence on antilung cancer.
3.1. Green tea polyphenols and lung cancer
Tea extract from the plant C. sinensis is the most common beverage for consumption world-
wide. Important data from different studies provide evidence that drinking tea can prevent 
carcinogenic effects [42, 43]. All activities related to a major component of green tea exert the 
effects of (−)-epigallocatechin gallate (EGCG). Some mechanisms showed that EGCG-induced 
apoptosis and cell-cycle arrest modulation in carcinogen-metabolizing enzymes and regulate 
cellular signaling pathways and inhibit transcription factors in cancer cells, resulting in the 
inhibition of cancer development, which facilitated the prevention and treatment by green tea 
and its composition, particularly EGCG.
Green tea can help prevent and treat lung cancer, especially EGCG and guanosine triphos-
phate (GTP). Dietary supplementation of EGCG (0.1, 0.3, and 0.5%) inhibited tumor growth 
in nude mice implanted with thymus H1299 cells. EGCG treatment increased phosphory-
lated histone 2A variants X and tumor cell apoptosis, as well as oxidative DNA damage 
assessment of the formation of 8-hydroxy-2′-deoxyguanosine (8-OHdG). This finding pres-
ents the first evidence of EGCG induction of ROS generation, leading to tumor cell DNA 
oxidative damage. EGCG is commonly referred to as a powerful antioxidant, but the current 
results showed that EGCG can also act as an antioxidant in some cases [44]. In different 
stages of an experimental lung cancer, EGCG and theaflavins have been proven to reduce 
the proliferation index in a benzo(a)pyrene[B(a)P]-induced lung carcinogenesis mouse 
model. When used theaflavins in 0.02 mg/mouse/day and EGCG dose of 0.01 mg/mouse/
day, results show that both of them reduced the obvious carcinoma and dysplasia in situ 
at 8th, 17th, and 26th weeks. In Swiss albino rats, GTP treatment and black tea polyphenols 
(BTP) at dosage of 0.1 and 0.2% resulted in low incidence of diethylnitrosamine-induced 
alveologenic tumors, which resulted in the inhibition of the expression of lung cancer caused 
by Akt, cyclooxygenase (COX)-2, and nuclear factor kappa-B (NF-κB) [45]. The combination 
of liquid Polyphenon E (0.25 or 0.25%) and atorvastatin-inhibited lung cancer induced by 
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in mice. Low-dose combination of 
Polyphenon E and atorvastatin significantly reduced the lung tumor diversity and enhanced 
cell apoptosis but inhibited tumor burden at myelogenous leukemia 1 (Mcl-1) level. Results 
show that lung tumors were effectively inhibited by atorvastatin and Polyphenon E, and in 
vitro and in vivo, the action between the two agents was synergistic. The inhibition activity 
of atomized difluoromethylornithine (DFMO) and Polyphenon E (1% wt/wt diet) admin-
istration was investigated in A/J mice injected with B(a)P. Polyphenon E did not suppress 
tumor treatment on average diversity but decreased the animal tumor load and significantly 
reduced the largest carcinoma [46].
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3.2. Isothiocyanates and lung cancer
Isothiocyanates (ITCs) existed in cruciferous vegetables, which are converted into glucose 
and ITC by the enzyme myrosinase. Benzyl isothiocyanate (BITC), phenethyl isothiocyanate 
(PEITC), and sulforaphane are widely studied for their chemopreventive and anticancer 
effects [47]. Recently, BITC-inhibited gefitinib-resistant human NSCLC growth, induction of 
apoptosis, caspase-3 activation, cell-cycle arrest in G2/M phase, ROS generation, glutathione 
depletion, inhibition of protein kinase activity, NF-κB transcription activation, and activation 
of mitogen-activated protein kinase (MAPK) and activating protein (AP)-1. PEITC declined 
the first phase of enzymes involved in the activation of several carcinogenic substances. 
PEITC also activated the second phase of enzyme activity, which is responsible for many 
carcinogenic metabolism and oxidative stresses. Isothiocyanates are proven to demonstrate 
anticancer behavior by inducing  apoptosis and inhibition of the cell-cycle stage.
Some reports showed that several mechanisms have been postulated to determine the ITC 
against the mechanism of lung cancer. Importantly, researchers thought that tubulin is 
one of the targets in the body for ITC binding and covalent binding of BITC, PEITC, sul-
foraphane tubulin. Binding with cell apoptosis induced the cell ability and mitosis arrest 
[48]. The effect of oral sulforaphane (9 μmol/mouse/day) in reducing the oxidative damage 
caused by B(a)P (100 mg/kg body weight, i.p.) in Swiss albino rats was determined. Oral 
sulforaphane reduced hydrogen peroxide production, increased the release of mitochon-
drial cytochrome c, and reduced the expression of Bcl2, Bax, and caspase-3. Newborn mice 
were exposed to cigarette smoke for 120 consecutive days, beginning at birth, as well as to 
budesonide in diet (2.4 mg/kg in diet) and PEITC (1000 mg/kg in diet) and N-acetylcysteine 
in drinking water (1000 mg/kg) of oral drugs, until 210 days. High incidence of benign lung 
tumor multiplicity and an increase in pulmonary malignant tumor exposure to cigarette 
smoke and budesonide were observed in the carcinogenicity of PEITC and NAC treat-
ment of mice lung exposed to cigarette smoke. Budesonide, PEITC, and NAC treatments 
reduced the yield of cigarette mainstream smoke, which induced lung benign or malignant 
tumor, showing mirror smokers’ intervention in the experimental situation. As compared 
with the NNK-treated control group, Conaway et al. investigated the influence of sulfora-
phane, PEITC, and NAC yoke compound progress/J mice lung adenoma and adenocarci-
noma [49] by reducing the incidence of adenocarcinoma PEITC in treated group of 3 and 
1.5 mmol/kg each diet and PEITC-NAC, which used in 8 and 4 mmol/kg each diet in treat-
ment group. Low incidence of lung cancer was showed in the treatment of sulforaphane-
NAC (8 and 4 mmol/kg diet) in the diet. The results show that sulforaphane, and NAC 
yoke, and PEITC compound reducing cell proliferation and inducing apoptosis in tobacco 
carcinogen-treated A/J mice and resulting in inhibited the progress of adenocarcinoma in 
lung adenoma [27]. The influence of PEITC diet (3 μmol/g diet) and BITC (1 μmol/g diet) 
and a mixture of BITC + PEITC (1 and 3 μmol/g diet) on hemoglobin (Hb) adducts of B(a)P 
and DNA and NNK and two urinary metabolites are worthy of investigation. In urine, 
NNAL-Gluc and 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) were measured. 
After 2 and 4 months, a significant reduction in the level of 4-hydroxy-1-(3-pyridyl)-1-bu-
tanone releasing DNA adducts of the NNK lung was caused by BITC + PEITC or PEITC, 
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whereas no effect was demonstrated by BITC. From 2 weeks to 12 weeks, BITC + PEITC 
or PEITC also inhibited the Hb adduct of NNK and showed no effect on B(a)P adduct. 
A significant increase in the NNK level was also observed in rats after treatment with 
NNAL and NNAL-Gluc PEITC, as well as with PEITC or BITC + PEITC [50]. These find-
ings suggest that PEITC or BITC + PEITC Hb released the DNA adduct formation in the 
lungs of mice that received B(a)P + nitrosamines. However, the BITC adduct was not influ-
enced by B(a)P or nitrosamines. Before each of the three carcinogenic polycyclic aromatic 
hydrocarbons (PAHs) were found in cigarettes, treatment with BITC (6.7 and 13.4 μmol) 
was performed: B(a)P, 5-methylchrysene (5-MeC), and dibenz[a,h] anthracene [DBahA]; 
Compared with beta hydroxyl acid (BHA) and sulforaphane, these PAHs more effectively 
inhibited lung tumor multiplicity [51].
3.3. Indole-3-carbinol and lung cancer
An autolysis product of glucosinolate has been reported to exert anticancer effects; this prod-
uct is indole-3-carbinol (I3C), which is present in Brassica plants like cabbage, cauliflower 
kale, broccoli, and Brussels sprouts [52].
After the postinitiation or progression protocol in A/J mice, we assessed how I3C inhib-
ited tobacco carcinogen–induced lung adenocarcinoma. After treatment with I3C during 
the postinitiation period, reduction was observed in the tumor multiplicity, hyperplastic 
foci, adenoma, adenoma with dysplasia, and adenocarcinoma. When I3C was given dur-
ing tumor progression, an increase was observed in the multiplicities of smaller tumors 
and decrease in larger tumors. I3C was found to efficiently inhibit the development of pul-
monary adenocarcinoma. Moreover, via modulation of the phosphatidylinositol-3-kinase 
(PI3K)/Akt signaling pathway, the anticancer effects of I3C were mediated [53]. Silibinin 
used in 7 μmol/g/diet and I3C used in 10 μmol/g each diet reduced the multiplicities of 
tumors on the adenocarcinoma and surface of the lung in NNK-treated mice. Additionally, 
as compared with I3C or silibinin alone, I3C and silibinin were strongly affect cyclin D1 
and poly (ADP-ribose) polymerase (PARP), p-Akt, p-ERK cleavage expression levels. Thus, 
against the development of lung cancer in A/J mice, this study proved that the findings of 
the combined treatment of silibinin and I3C afforded more protection and can be used to 
prevent cancer in current and former smokers [54]. Investigation of this effect showed that 
I3C (100 or 150 μM) on vinyl carbamate (VC) induced deregulation of microRNA (miRNA) 
levels in lung tissues of female A/J mice. Compared with mice treated with VC alone, the 
miR-21, mir-31, miR-130a, miR-146b, and miR-377 expression levels decreased in mice 
treated with VC and I3C in their diet. The development of lung cancer showed a signifi-
cant relationship with abnormal miRNA expression. In lung tumors, compared with normal 
lungs, the results explained distinctive changes in the expression of several miRNAs. I3C 
exerted effects on most of the miRNAs. Myo-inositol (MI; 56 μmol/g/diet) and I3C (30 or 
70 μmol/g/diet) against VC-induced lung cancer were applied. With higher dose on the lung 
surface, incidence of cancer, multiplicity, size, and adenoma with cellular pleomorphism, 
the lower dose of I3C showed fewer effects, whereas the higher dose of I3C decreased the 
multiplicities of tumors on treatment of mice. IκBα degradation, NF-κB activation, COX-2, 
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p-Akt, and activation of caspase-3 and PARP cleavage were  inhibited by treatment with 
higher dose of I3C [55].
3.4. Genistein and lung cancer
The most abundant isoflavone in soybean, genistein (4,5,7-trihydroxyisoflavone), has been 
widely reported for its chemotherapeutic and chemopreventive effects. Recently, lung tumor 
growth was suppressed in vivo in a dose-dependent manner and apparently showed no toxic-
ity on a derivative of genistein, 7-difluoromethyl-5,4′-dimethoxygenistein [56]. A significant 
decrease in tumor growth was found in a xenograft model for treatment of mice with a com-
bination of gefitinib and genistein [57]. During the phase of pneumonitis, in rats receiving 
genistein (750 mg/kg body weight), the increase of breathing rate was inhibited after irradia-
tion with 18 Gy at approximately 0.5 Gy/min and a delay of 50–80 days in Sprague-Dawley 
rats. After irradiation for 28 weeks and treatment with genistein, TNF-α, IL-1β, TGF-β, and 
collagen also decreased. The levels of 8-OHdG content also decreased, and the protection 
against DNA damage was measured in surviving rats. Treatment with genistein after irradia-
tion indicated that DNA damage is caused by the production of ROS, which also reduced 
DNA damage in the form of micronuclear formation [57].
For lung metastasis induced by B16F-10 melanoma cells in C57BL/6 mice, the inhibition 
effects of dietary soybean isoflavones, genistein, and daidzein were investigated. Compared 
with untreated tumor-bearing animals, treatment with genistein (200 μmol/kg body weight) 
caused lung tumor nodule formation inhibition, and the lung collagen hydroxyproline con-
tent and serum sialic acid level were inhibited. The life span of the tumor-bearing animals was 
also increased by treatment with genistein [58].
3.5. Curcumin and lung cancer
Curcumin (diferuloylmethane) is derived from the plant C. longa. The antiangiogenic, analge-
sic, antioxidant, anti-inflammatory, and antiseptic properties of curcumin have been widely 
studied [59].
Experiments showed that curcumin (0.6%) can decrease the expression of COX2 in subcu-
taneous tumor in vivo and the weight of intralung tumors but can increase the survival rate. 
Curcumin also increased the survival of athymic nude mice and inhibited the tumor growth 
of orthotopic human NSCLC xenografts [60]. Curcumin and erlotinib significantly inhib-
ited tumor growth of erlotinib-resistant NSCLC cells in vivo compared with the control, and 
this finding suggested that during treatment with erlotinib, curcumin might be a prospec-
tive adjuvant for NSCLC patients. The growth of human lung cancer xenografts in nude 
mice was inhibited by oral intake of curcumin (500 mg/kg/body/day) and phosphosulindac 
(200 mg/kg/day); curcumin may improve the phosphosulindac bioavailability and inhibition 
of efflux transporters [61]. Curcumin (50-mg/kg body weight) was found to increase cell 
survival, which contributed to T-cell–mediated adaptive immune response and decrease in 
tumor growth. Low-dose curcumin increased T cells derived from 3LL-tumor-bearing mice, 
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 particularly CD8+ T cells, but high-dose curcumin (100-mg/kg body weight) decreased T cells 
which exhibited the enhancement of cytotoxicity and interferon-γ (IFN-γ) secretion and pro-
liferation against 3LL tumor cells. In lung-tumor-bearing models, the results pointed out that 
curcumin may support the immune system and induce antitumor immune response via the 
T-cell-mediated effect. Cancer treatment by curcumin can prove it as an immunologically 
safe drug. These data provide further evidence that curcumin can play a role in lung cancer 
therapy [62].
3.6. Fisetin and lung cancer
Fisetin (3,3′,4′,7-tetrahydroxyflavone) is found in strawberry, persimmon, grape, apple, 
cucumber, and onion. It is a naturally occurring flavonoid with apoptotic and antiangiogenic 
properties, as well as antiproliferative effects in cancer cells [63].
A previously published study showed that treatment with fisetin (25-mg/kg body weight) 
decreased histological lesions and lipid peroxidation levels and modulated the enzymatic 
and nonenzymatic antioxidants in B(a)P-treated Swiss albino mice [64]. In LLC-bearing mice, 
Matrigel plug assay showed that when fisetin was treated with dose of 223 mg/kg inhibited 
angiogenesis. Tumor growth was also inhibited by fisetin, which is similar to the effect of 
low-dose cyclophosphamide (30-mg/kg body weight). Combination of fisetin and cyclophos-
phamide led to the striking improvement in antitumor activity and decrease in microvessel 
density and low systemic toxicity. Fisetin exhibited anticancer activities and antiangiogenic 
properties in LLC-bearing mice.
3.7. Pomegranate polyphenols and lung cancer
Pomegranate (Punica granatum, Punicaceae) was cultivated in Afghanistan, India, China, 
Japan, Russia, and the United States. It is an edible fruit widely comprising about 80% juice 
and 20% seed.
Pomegranate can provide oral administration of pomegranate fruit extract (PFE), which 
caused tumor growth inhibition in athymic nude mice implanted with human lung cancer 
A549 cells. Pomegranate can induce the appearance of small solid tumors, which prolonged 
survival time in animal models [65]. B(a)P and N-nitroso-tris-chloroethylurea (NTCU) in A/J 
mice were investigated, caused of effects of oral consumption of a human-achievable dose of 
PFE dose of 0.2%, w/v effect on progression, angiogenesis, growth, and signaling pathways in 
two models of lung cancer. For treatment with PFE and B(a)P or NTCU, we found little lung 
tumor multiplicities of tumor incidence in mice. Oral administration of PFE caused inhibition 
of NF-κB, MAPK, and PI3K, as well as phosphorylation of Akt, mammalian target of rapamy-
cin (mTOR), c-met, and lung markers that inhibited B(a)P- and NTCU-treated mice; cell pro-
liferation and angiogenesis were also inhibited. By targeting multiple signaling pathways and 
associated events, PFE demonstrated activity against lung cancer, and these events are critical 
for the development and progression of lung carcinoma [66]. Molecular targets of antilung 
cancer natural product molecules in the body were shown in Table 1.
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4. Natural product molecules for the treatment of lung cancer 
in clinical trials
Complementary and alternative medicine (CAM), including natural product molecules, 
increased survival in cancer patients [67]. Recently, 453 cancer patients in a cohort study 
showed that 77% of patients use herbal medicines combined with conventional treatment to 
reduce the therapy-associated toxicity and cancer-related symptoms, improve the immune 
system, and even eliminate cancer directly [68].
Conventional chemotherapy is combined with natural product molecules to increase the ther-
apeutic effect and QoL. Sixty-three in-patients diagnosed with IV NSCLC and stage IIIb were 
treated as randomized-controlled trial, Gujin granules (Jiangyin Tianjiang Pharmaceutical Co., 
China) and Shengmai injection (Ya’an Sanjiu Pharmaceutical Co., China) were administered 
intravenously and orally. Navelbine and cisplatin (NP) chemotherapy were treated in all the 
groups. This combination therapy enhanced median survival time (P = 0.014) and response 
rate to 48.5% (16/33) compared to untreated control (32.2% = 9/28) in the control group (P 
= 0.0373). However, herbal medicine did not affect the bone marrow inhibition occurrence, 
median time to progression, 1-year survival rate, and mean cycles of chemotherapy applied. 
Among 232 NSCLC patients, by using the QoL scale of the European Organization for Research 
on Treatment of Cancer (QLQ-C30) (Lin and Li, 2007), treated with Shenqi-fuzheng injection 
(Lizhu Co., China), improved QoL and the response rate. In another trail, Yiqi Yangyin Jiedu 
Decoction significantly increased the immunological parameters and Karnofsky (KPS) score, 
including CD4+, CD4+/CD8+, CD3+, and CD8+/CD28+, and all the patients were treated with NP 
or gemcitabine and cisplatin (GP) compared with the untreated control [69].
Natural product molecules can improve the QoL of patients with lung cancer. Recently, QoL 
is improved in NSCLC patients with long-term prognostic factors of survival. In a RCT and 
herbal Feiji recipe, Feiji was found to improve the clinical therapeutic effect, reduce the side 
effects of chemotherapy before this research by adding higher scores in the role, as well as the 
social and economic status (P < 0.05 or P < 0.01) based on the QLQ C30 questionnaire. Similarly, 
Active natural products for antilung cancer Molecular targets
Green tea MAPK mTOR EGFR p53 PKC TGF-β
Isothiocyanates MAPK AP-1 NF-κB Akt Nrf2 Keap1
Genistein EGFR PGE2 Akt NF-κB Cox-2 TNF-α
Pomegranate PI3K Akt mTOR MAPK c-met NF-κB
Fisetin Akt mTOR PI3K AMPKα AP-1 NF-κB
Curcumin Wnt/β-catenin Cox-2 NF-κB EGFR STAT-3 Survivin
Indole-3-carbinol IL-6 IL-1β p53 PI3K Akt Cox-2
Table 1. Antilung cancer natural product molecules in the body and molecular targets.
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in a  clinical trial of 294 patients with advanced NSCLC and treated with Shenfu injection of 
traditional Chinese medicine, on the basis of the functional assessment of cancer therapy-lung 
(FACT-L), Chinese medicine positively affected health when used alone, as well as with emo-
tional,  functional, and additional care when performing traditional chemotherapy (P < 0.05) [70].
The negative influence of natural product molecules is shown by traditional intervention. 
One of the main risks of conventional treatment is pneumonia in patients with lung cancer, 
and this complication may be caused by radiation therapy intervention and symptoms of 
severe dyspnea, cough, fever, respiratory failure and/or verticillium wilt in severe cases. With 
Dixiong soup in clinical trials of 46 NSCLC patients who underwent radiotherapy, based on 
the incidence of pneumonia after radiotherapy and QoL using continued to shrink the clinical 
imaging physical difficulty breathing (CRP) score, tumor radiotherapy group (RTOG) rating 
scores, and KPS score, Dixiong Shang Xianzhu reduced the incidence of radioactive pneu-
monia (treatment, 10.0%; control, 26.3%; P = 0.0032) and improved the continued decline of 
CRP dyspnea score, RTOG classification score (P < 0.05), and KPS score (P < 0.01). Similarly, 
substantial evidence demonstrated good effect of herbal Liangxue jiedu huoxue soup, Qingjin 
runfei decoction, and Shenqi fuzheng injection. Hydrochloric acid, stand for kang, topoisom-
erase inhibitors, and Chinese tree Camptotheca acuminata (Cornaceae) are used for lung can-
cer treatment combined with other conventional drugs, in spite of the side effects including 
leukopenia and diarrhea. With Hangeshash into RCTs, 44 irinotecan-treated NSCLC patients 
showed that TJ-14 can significantly improve the grade (P = 0.044) and frequency of diarrhea to 
grades 3 and 4 (P = 0.018). A list of therapeutic approaches and outcome assessment and the 
quality of herbal medication were listed in Table 2 [71].
CHM formula No. of participants/
dropout or 
withdrawal
TNM stage Control group 
intervention
Assessment of 
outcome
Duration 
(week)
Jadad scale
Shengmai 
injection Gujin 
grand decoction
106/6 dropout 
patients
IIIB–IV NP Tumor response, 
survival rate, 
chemotoxicity
12 3
Feiji recipe 77/0 IIIB–IV NP/TP Tumor response, 
survival rate, CD62P
8 3
Yinqi Yangyin 
decoction
60/3 withdrawals IIIB–IV GP Tumor response, 
survival rate, 
chemotoxicity, KPS
8 3
Fuzheng Kangai 
decoction
129/drop out: 5 
patients in CTC 
and 4 patients in 
CT; withdraw: 2 
patients in CTC and 
3 patients in CT
IIIB–IV MVP 
combined with 
radiotherapy
Tumor response, 
chemotoxicity, KPS
12 3
Shengmai 
injection
60/0 IIB–IV DP Tumor response, 
chemotoxicity
8 3
Table 2. Therapeutic approaches and outcome assessment of herbal medication.
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5. Constraints and current clinical trials and the challenges of 
natural product molecules
The traditional Chinese medicine (TCM) clinical research also presents some limitations and 
difficulties. As mentioned in a recent review, TCM, including herbal medicine, establishes 
its unique features, such as holism and personalization. According to the theory of tradi-
tional Chinese medicine, a patient is diagnosed with symptoms rather than the disease itself 
and prescribed with a personalized herbal formula to treat the symptoms. Although RCT 
is a powerful tool to verify the clinical curative effect of health care, a RCT on the appli-
cation of personalized herbs remains a challenge because of heterogeneous batch manage-
ment. Likewise, Chinese medicine intervention heterogeneity leads to some difficulties for 
high-performance analysis of natural product molecules. Therefore, for cancer research in the 
future, particularly on herbs and plant chemicals, we suggest that the quality control should 
be performed consistently with batch and pharmacokinetic studies on TCM and its compo-
nents, which perform antitumor activities in lung cancer.
There still exist some problems to standardize in the use of natural products in prevention or 
treatment lung cancer. First, the purity of traditional Chinese medicine is not high, most of the 
traditional Chinese medicine preparations from to the original drug, powder, or crude extract, so 
it works slowly. Second, inconvenient to use, taking traditional Chinese medicine generally to a 
large package of herbs, and not easy to drink because of bitterness. Third, the dose of natural prod-
ucts is difficult to grasp, and the available activity contents are different due to the different plants.
As a result, the problems should be specified to herbs in the QoL in a sense, and the therapeu-
tic effect may vary among different batches. Furthermore, the lack of rigorous methods, risk 
of possible bias, and a relatively small number of patients involved were repeatedly pointed 
out in the previous literature on herbal application in lung cancer patients.
However, the most recent basic and clinical research showed a growing body of evidence 
to support the notion indicating that herbs may be beneficial and effective in the treatment 
and improvement of the QoL of patients with lung cancer, as well as prevent the side effects 
of conventional therapy and improve the immune parameters. However, researchers must 
develop novel specific methods to completely solve the challenges of the present study and 
verify the credibility of possible herbs.
Despite the great progress of lung cancer treatment, lung cancer remains a leading cause of 
cancer death worldwide. Molecule-targeted therapy has recently attracted research attention; 
for example, the treatment of tyrosine kinase inhibitors and erlotinib for epidermal growth 
factor receptor (EGFR) and its downstream mTOR signaling factors and bevacizumab, as 
well as humanized monoclonal antibody, can bind to VEGF to increase the response rate and 
progression-free survival (PFS) of patients on treatment with carboplatin, paclitaxel, cisplatin, 
and gemcitabine in phase II trials. Plenty of evidence from a  previous study showed that the 
eastern medicine herbal therapy is effective in lung cancer treatment by regulating cell prolif-
eration, apoptosis, angiogenesis, and metastasis in multidrug-resistant tuberculosis patients. 
These activities can participate in a biological process of target molecule toxicity to normalize 
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lung epithelial cells in lung cancer. Although various herbal formulas and plants are tradition-
ally used to treat lung diseases since the ancient times, the folk prescription of lung cancer 
guidelines and standards is the first published by the American College of Chest Physicians 
including complementary and alternative medicine in 2007, as well as the systematic review of 
the potential of herbs and its active compounds in lung cancer treatment without execution. In 
the current review, we recommend the potential of herbs and plant chemicals, which are com-
monly used for the treatment of lung diseases, including cancer, for folk prescription of critical 
data analysis and discussion in vitro or in vivo laboratory experimental models and clinical 
trials. Overall, we conclude that herbs and plant chemicals are potentially effective anticancer 
drugs for the treatment and prevention of lung cancer by adjusting the multimolecular targets 
involved in angiogenesis, metastasis, and serious side effects, thereby providing only quality 
control and reproducibility of problem solving.
Author details
Wei-long Zhong1, Yuan Qin1, Shuang Chen2 and Tao Sun1*
*Address all correspondence to: sunrockmia@hotmail.com
1 State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai 
University, Tianjin, People’s Republic of China
2 Tianjin Key Laboratory of Molecular Drug Research, Tianjin International Joint Academy of 
Biomedicine, Tianjin, People’s Republic of China
References
[1] Gorlova, O.Y., et al., Aggregation of cancer among relatives of never-smoking lung can-
cer patients. Int J Cancer, 2007. 121(1): pp. 111–8.
[2] Catelinois, O., et al., Lung cancer attributable to indoor radon exposure in France: impact 
of the risk models and uncertainty analysis. Environ Health Perspect, 2006. 114(9): pp. 
1361–6.
[3] Broker, L.E. and G. Giaccone, The role of new agents in the treatment of non-small cell 
lung cancer. Eur J Cancer, 2002. 38(18): pp. 2347–61.
[4] Kukunoor, R., J. Shah, and T. Mekhail, Targeted therapy for lung cancer. Curr Oncol 
Rep, 2003. 5(4): pp. 326–33.
[5] Hirsch, F.R., et al., Epidermal growth factor family of receptors in preneoplasia and lung 
cancer: perspectives for targeted therapies. Lung Cancer, 2003. 41(Suppl 1): pp. S29–42.
[6] Jacobson, M.D., J.F. Burne, and M.C. Raff, Mechanisms of programmed cell death and 
Bcl-2 protection. Biochem Soc Trans, 1994. 22(3): pp. 600–2.
Antitumor Effect of Natural Product Molecules against Lung Cancer
http://dx.doi.org/10.5772/67241
215
[7] Yang, Y.C., et al., Enhancement of glucose uptake in 3 T3-L1 adipocytes by Toona sinensis 
leaf extract. Kaohsiung J Med Sci, 2003. 19(7): pp. 327–33.
[8] Li, M., X. Li, and J.C. Li, Possible mechanisms of trichosanthin-induced apoptosis of 
tumor cells. Anat Rec (Hoboken), 2010. 293(6): pp. 986–92
[9] Hsu, Y.L., et al., Acacetin-induced cell cycle arrest and apoptosis in human non-small 
cell lung cancer A549 cells. Cancer Lett, 2004. 212(1): pp. 53–60.
[10] Wang, J.Y., et al., Effects of Feiyanning Decoction on gene expression of nuclear fac-
tor-kappaB activated by tumor necrosis factor-alpha in lung adenocarcinoma cell line. 
Zhong Xi Yi Jie He Xue Bao, 2009. 7(3): pp. 249–54.
[11] Gomathinayagam, R., et al., Anticancer mechanism of plumbagin, a natural compound, 
on non-small cell lung cancer cells. Anticancer Res, 2008. 28(2A): pp. 785–92.
[12] Hsu, H.F., et al., Glossogin, a novel phenylpropanoid from Glossogyne tenuifolia, induced 
apoptosis in A549 lung cancer cells. Food Chem Toxicol, 2008. 46(12): pp. 3785–91.
[13] Kilarski, W.W., et al., An in vivo neovascularization assay for screening regulators of 
angiogenesis and assessing their effects on pre-existing vessels. Angiogenesis, 2012. 
15(4): pp. 643–55.
[14] Revannasiddaiah, S. and S.P. Susheela, Chemically enhanced radiotherapy: visions for 
the future. Ann Transl Med, 2016. 4(3): p. 52.
[15] Cao, Y., Future options of anti-angiogenic cancer therapy. Chin J Cancer, 2016. 35: p. 21.
[16] Hsu, C.L. and G.C. Yen, Ganoderic acid and lucidenic acid (triterpenoid). Enzymes, 2014. 
36: pp. 33–56.
[17] Dan, X., et al., A ribonuclease isolated from wild Ganoderma lucidum suppressed 
autophagy and triggered apoptosis in colorectal cancer cells. Front Pharmacol, 2016. 
7: p. 217.
[18] Saylam Kurtipek, G., et al., Resolution of cutaneous sarcoidosis following topical application 
of Ganoderma lucidum (reishi mushroom). Dermatol Ther (Heidelb), 2016. 6(1): pp. 105–9.
[19] Kim, T.H., et al., Induction of apoptosis in MCF7 human breast cancer cells by Khz 
(fusion of Ganoderma lucidum and Polyporus umbellatus mycelium). Mol Med Rep, 2016. 
13(2): pp. 1243–9.
[20] Gao, Y., et al., Effects of water-soluble Ganoderma lucidum polysaccharides on the immune 
functions of patients with advanced lung cancer. J Med Food, 2005. 8(2): pp. 159–68.
[21] Lee, J.M., et al., Inflammation in lung carcinogenesis: new targets for lung cancer chemo-
prevention and treatment. Crit Rev Oncol Hematol, 2008. 66(3): pp. 208–17.
[22] Han, M., Y. Song, and X. Zhang, Quercetin suppresses the migration and invasion in 
human colon cancer Caco-2 cells through regulating toll-like receptor 4/nuclear factor-
kappa B pathway. Pharmacogn Mag, 2016. 12(Suppl 2): pp. S237–44.
A Global Scientific Vision - Prevention, Diagnosis, and Treatment of Lung Cancer216
[23] Jiang, Q., et al., Lunasin suppresses the migration and invasion of breast cancer cells by 
inhibiting matrix metalloproteinase-2/-9 via the FAK/Akt/ERK and NF-kappaB signal-
ing pathways. Oncol Rep, 2016. 36(1): pp. 253–62.
[24] Hipfner, D.R., et al., Monoclonal antibodies that inhibit the transport function of the 190-
kDa multidrug resistance protein, MRP. Localization of their epitopes to the nucleotide-
binding domains of the protein. J Biol Chem, 1999. 274(22): pp. 15420–6.
[25] Lima, J.P., et al., Optimal duration of first-line chemotherapy for advanced non-small 
cell lung cancer: a systematic review with meta-analysis. Eur J Cancer, 2009. 45(4): pp. 
601–7.
[26] Einhorn, L.H., First-line chemotherapy for non-small-cell lung cancer: is there a superior 
regimen based on histology? J Clin Oncol, 2008. 26(21): pp. 3485–6.
[27] Abou-Mourad, Y., et al., Docetaxel and irinotecan as first-line chemotherapy in patients 
with advanced non-small-cell lung cancer: a pilot study. J Med Liban, 2008. 56(1): pp. 
16–21.
[28] Sadava, D., et al., Effect of Ganoderma on drug-sensitive and multidrug-resistant small-
cell lung carcinoma cells. Cancer Lett, 2009. 277(2): pp. 182–9.
[29] Sadava, D., et al., Effects of four Chinese herbal extracts on drug-sensitive and mul-
tidrug-resistant small-cell lung carcinoma cells. Cancer Chemother Pharmacol, 2002. 
49(4): pp. 261–6.
[30] Thomas, S.L., et al., Activation of the p38 pathway by a novel monoketone curcumin 
analog, EF24, suggests a potential combination strategy. Biochem Pharmacol, 2010. 
80(9): pp. 1309–16.
[31] Xu, M., et al., Reversal effect of Stephania tetrandra-containing Chinese herb formula 
SENL on multidrug resistance in lung cancer cell line SW1573/2R120. Am J Chin Med, 
2010. 38(2): pp. 401–13.
[32] Trachootham, D., J. Alexandre, and P. Huang, Targeting cancer cells by ROS-mediated 
mechanisms: a radical therapeutic approach?. Nat Rev Drug Discov, 2009. 8(7): 
pp. 579–91.
[33] Faux, S.P., et al., The role of oxidative stress in the biological responses of lung epithelial 
cells to cigarette smoke. Biomarkers, 2009. 14(Suppl 1): pp. 90–6.
[34] Dandona, P., et al., Angiotensin II receptor blocker valsartan suppresses reactive oxygen 
species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal 
subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab, 2003. 88(9): 
pp. 4496–501.
[35] Binda, M.M., et al., Effect of reactive oxygen species scavengers, antiinflammatory 
drugs, and calcium-channel blockers on carbon dioxide pneumoperitoneum-enhanced 
adhesions in a laparoscopic mouse model. Surg Endosc, 2007. 21(10): pp. 1826–34.
Antitumor Effect of Natural Product Molecules against Lung Cancer
http://dx.doi.org/10.5772/67241
217
[36] Ghanim, H., et al., An antiinflammatory and reactive oxygen species suppressive effects 
of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab, 
2010. 95(9): pp. E1–8.
[37] Li, Y.B., et al., Protective, antioxidative and antiapoptotic effects of 2-methoxy-6-ace-
tyl-7-methyljuglone from Polygonum cuspidatum in PC12 cells. Planta Med, 2011. 77(4): 
pp. 354–61.
[38] Shin, J.A., et al., Apoptotic effect of Polygonum cuspidatum in oral cancer cells through the 
regulation of specificity protein 1. Oral Dis, 2011. 17(2): pp. 162–70.
[39] Lawless, M.W., K.J. O'Byrne, and S.G. Gray, Oxidative stress induced lung cancer and 
COPD: opportunities for epigenetic therapy. J Cell Mol Med, 2009. 13(9A): pp. 2800–21.
[40] Kachadourian, R., et al., Casiopeina IIgly-induced oxidative stress and mitochondrial dys-
function in human lung cancer A549 and H157 cells. Toxicology, 2010. 268(3): pp. 176–83.
[41] Lee, Y.M., et al., Inhibition of glutamine utilization sensitizes lung cancer cells to api-
genin-induced apoptosis resulting from metabolic and oxidative stress. Int J Oncol, 2016. 
48(1): pp. 399–408.
[42] Jin, L., et al., Epigallocatechin gallate promotes p53 accumulation and activity via the 
inhibition of MDM2-mediated p53 ubiquitination in human lung cancer cells. Oncol 
Rep, 2013. 29(5): pp. 1983–90.
[43] Liu, L.C., et al., EGCG inhibits transforming growth factor-beta-mediated epithelial-to-
mesenchymal transition via the inhibition of Smad2 and Erk1/2 signaling pathways in 
nonsmall cell lung cancer cells. J Agric Food Chem, 2012. 60(39): pp. 9863–73.
[44] Li, G.X., et al., Pro-oxidative activities and dose-response relationship of (-)-epigallocat-
echin-3-gallate in the inhibition of lung cancer cell growth: a comparative study in vivo 
and in vitro. Carcinogenesis, 2010. 31(5): pp. 902–10.
[45] Roy, P., et al., Tea polyphenols inhibit cyclooxygenase-2 expression and block activation 
of nuclear factor-kappa B and Akt in diethylnitrosoamine induced lung tumors in Swiss 
mice. Invest New Drugs, 2010. 28(4): pp. 466–71.
[46] Katiyar, S.K., R. Agarwal, and H. Mukhtar, Protective effects of green tea polyphenols 
administered by oral intubation against chemical carcinogen-induced forestomach and 
pulmonary neoplasia in A/J mice. Cancer Lett, 1993. 73(2–3): pp. 167–72.
[47] Shapiro, T.A., et al., Chemoprotective glucosinolates and isothiocyanates of broccoli 
sprouts: metabolism and excretion in humans. Cancer Epidemiol Biomarkers Prev, 2001. 
10(5): pp. 501–8.
[48] Mi, L., et al., Covalent binding to tubulin by isothiocyanates. A mechanism of cell growth 
arrest and apoptosis. J Biol Chem, 2008. 283(32): pp. 22136–46.
[49] Balansky, R., et al., Prevention of cigarette smoke-induced lung tumors in mice by 
budesonide, phenethyl isothiocyanate, and N-acetylcysteine. Int J Cancer, 2010. 126(5): 
pp. 1047–54.
A Global Scientific Vision - Prevention, Diagnosis, and Treatment of Lung Cancer218
[50] Boysen, G., et al., Effects of benzyl isothiocyanate and 2-phenethyl isothiocyanate on 
benzo[a]pyrene and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone metabolism in 
F-344 rats. Carcinogenesis, 2003. 24(3): pp. 517–25.
[51] Hecht, S.S., et al., Benzyl isothiocyanate: an effective inhibitor of polycyclic aromatic 
hydrocarbon tumorigenesis in A/J mouse lung. Cancer Lett, 2002. 187(1–2): pp. 87–94.
[52] Steinmetz, K.A. and J.D. Potter, Vegetables, fruit, and cancer prevention: a review. J Am 
Diet Assoc, 1996. 96(10): pp. 1027–39.
[53] Qian, X., et al., Indole-3-carbinol inhibited tobacco smoke carcinogen-induced lung ade-
nocarcinoma in A/J mice when administered during the post-initiation or progression 
phase of lung tumorigenesis. Cancer Lett, 2011. 311(1): pp. 57–65.
[54] Dagne, A., et al., Enhanced inhibition of lung adenocarcinoma by combinatorial treat-
ment with indole-3-carbinol and silibinin in A/J mice. Carcinogenesis, 2011. 32(4): 
pp. 561–7.
[55] Kassie, F., et al., Inhibition of vinyl carbamate-induced pulmonary adenocarcinoma by 
indole-3-carbinol and myo-inositol in A/J mice. Carcinogenesis, 2010. 31(2): pp. 239–45.
[56] Peng, B., et al., Inhibition of proliferation and induction of G1-phase cell-cycle arrest 
by dFMGEN, a novel genistein derivative, in lung carcinoma A549 cells. Drug Chem 
Toxicol, 2013. 36(2): pp. 196–204.
[57] Zhu, H., et al., Synergistic inhibitory effects by the combination of gefitinib and genistein 
on NSCLC with acquired drug-resistance in vitro and in vivo. Mol Biol Rep, 2012. 39(4): 
pp. 4971–9.
[58] Menon, L.G., et al., Effect of isoflavones genistein and daidzein in the inhibition of lung 
metastasis in mice induced by B16F-10 melanoma cells. Nutr Cancer, 1998. 30(1): pp. 74–7.
[59] Ye, M.X., et al., Curcumin: updated molecular mechanisms and intervention targets in 
human lung cancer. Int J Mol Sci, 2012. 13(3): pp. 3959–78.
[60] Lev-Ari, S., et al., Curcumin induces apoptosis and inhibits growth of orthotopic human 
non-small cell lung cancer xenografts. J Nutr Biochem, 2014. 25(8): pp. 843–50.
[61] Cheng, K.W., et al., Curcumin enhances the lung cancer chemopreventive efficacy 
of phospho-sulindac by improving its pharmacokinetics. Int J Oncol, 2013. 43(3): 
pp. 895–902.
[62] Moghaddam, S.J., et al., Curcumin inhibits COPD-like airway inflammation and lung 
cancer progression in mice. Carcinogenesis, 2009. 30(11): pp. 1949–56.
[63] Arai, Y., et al., Dietary intakes of flavonols, flavones and isoflavones by Japanese women 
and the inverse correlation between quercetin intake and plasma LDL cholesterol con-
centration. J Nutr, 2000. 130(9): pp. 2243–50.
[64] Ravichandran, N., et al., Fisetin, a novel flavonol attenuates benzo(a)pyrene-induced 
lung carcinogenesis in Swiss albino mice. Food Chem Toxicol, 2011. 49(5): pp. 1141–7.
Antitumor Effect of Natural Product Molecules against Lung Cancer
http://dx.doi.org/10.5772/67241
219
[65] Khan, N., et al., Pomegranate fruit extract inhibits prosurvival pathways in human A549 
lung carcinoma cells and tumor growth in athymic nude mice. Carcinogenesis, 2007. 
28(1): pp. 163–73.
[66] Khan, N., et al., Oral consumption of pomegranate fruit extract inhibits growth and pro-
gression of primary lung tumors in mice. Cancer Res, 2007. 67(7): pp. 3475–82.
[67] Boon, H.S., F. Olatunde, and S.M. Zick, Trends in complementary/alternative medi-
cine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC 
Women’s Health, 2007. 7: p. 4.
[68] Richardson, M.A., et al., Complementary/alternative medicine use in a comprehensive 
cancer center and the implications for oncology. J Clin Oncol, 2000. 18(13): pp. 2505–14.
[69] Liu, L.S., J.X. Liu, and C.J. Li, Clinical effect of yiqi yangyin jiedu decoction in treating 
patients with advanced non-small cell lung cancer. Zhongguo Zhong Xi Yi Jie He Za Zhi, 
2008. 28(4): pp. 352–5.
[70] Lin, L.Z., D.H. Zhou, and X.T. Zheng, Effect of traditional Chinese medicine in improv-
ing quality of life of patients with non-small cell lung cancer in late stage. Zhongguo 
Zhong Xi Yi Jie He Za Zhi, 2006. 26(5): pp. 389–93.
[71] Li, S.G., H.Y. Chen, C.S. Ou-Yang, et al., The efficacy of Chinese herbal medicine as an 
adjunctive therapy for advanced non-small cell lung cancer: a systematic review and 
meta-analysis. PLoS One, 2013. 8(2): p. e57604.
A Global Scientific Vision - Prevention, Diagnosis, and Treatment of Lung Cancer220
